Related Experiment Video

Updated: Nov 26, 2025

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
06:49

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians

Published on: March 14, 2014

11.9K

Isavuconazole as Salvage Therapy for Refractory Pediatric Coccidioidal Meningitis

Fouzia Naeem1,2, Fred Laningham3, Brenik Kuzmic4

  • 1From the Department of Infectious Disease, Valley Children's Healthcare, Madera.

The Pediatric Infectious Disease Journal
|December 14, 2020
PubMed

Insights

Coccidioidal meningitis is challenging to treat. Isavuconazole, a newer antifungal, stabilized a pediatric case refractory to other treatments, showing promise for this difficult-to-treat fungal infection.

Area of Science:

  • Mycology
  • Infectious Diseases
  • Pediatric Neurology

Background:

  • Coccidioidal meningitis is a severe fungal infection of the central nervous system, often difficult to manage.
  • Standard antifungal therapies can have significant side effects and variable efficacy.
  • The newer triazole, isavuconazole, offers a potentially improved safety and efficacy profile for invasive fungal infections.

Observation:

  • A pediatric patient presented with refractory coccidioidal meningitis.
  • Previous treatments with other antifungal agents failed to achieve disease control.
  • The patient's condition was refractory, indicating a need for alternative therapeutic strategies.

Findings:

  • Treatment with isavuconazole led to stabilization of the coccidioidal meningitis.
  • The patient showed clinical improvement following the initiation of isavuconazole therapy.
  • Isavuconazole demonstrated efficacy in a challenging pediatric case after failure of other antifungals.

Implications:

  • Isavuconazole represents a potential therapeutic option for refractory coccidioidal meningitis in pediatric patients.
  • This case highlights the expanding role of newer azoles in managing complex fungal infections.
  • Further research is warranted to establish the long-term efficacy and safety of isavuconazole in pediatric coccidioidal meningitis.

More Related Videos

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema08:44

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema

Published on: September 1, 2016

9.1K
A Contemporary Warming/Restraining Device for Efficient Tail Vein Injections in a Murine Fungal Sepsis Model06:02

A Contemporary Warming/Restraining Device for Efficient Tail Vein Injections in a Murine Fungal Sepsis Model

Published on: November 6, 2020

16.9K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
110
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
109
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
596
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
317
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
104
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
90